Clinical trials: Cancer (Solid Tumors)
Solid Tumors
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally twice daily to patients with advanced…
- Trial name
- NCT00921869
- Testing
- E7050
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Eisai Co., Ltd.
Solid Malignancies
Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.
- Trial name
- NCT06933069
- Testing
- CMAB017
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Advanced Solid Tumors
Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
- Trial name
- NCT00519662
- Testing
- SNS-314
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sunesis Pharmaceuticals
Solid Tumor
A Study of AK131 in Patients With Advanced Solid Tumors
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
- Trial name
- NCT06166888
- Testing
- AK131
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Akeso
Herpes Zoster, Herpes Zoster Vaccine
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.
- Trial name
- NCT01798056
- Testing
- GSK 1437173A
- Where
- 28 sites in Canada, Czechia and 4 more
- Volunteers
- 237 people
- Sponsor
- GlaxoSmithKline
Solid Tumor
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.
- Trial name
- NCT01363024
- Testing
- MFGR1877S
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Metastatic Solid Tumors
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced…
- Trial name
- NCT01449370
- Testing
- TAK-117
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 125 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumors
Japanese Phase 1 Trial of Sym004 in Solid Tumors
This trial is to assess the safety and tolerability of Sym004, administered weekly or biweekly as monotherapy in Japanese subjects with advanced solid tumors.This study consisted of two parts, a dose-escalation part ("Part-A")…
- Trial name
- NCT01955473
- Testing
- Sym004
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07318805
- Testing
- PF-08032562, Fulvestrant, Cetuximab
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- Pfizer
Advanced Solid Tumor
CVL006 Combination Therapy in Advanced Solid Tumors
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with…
- Trial name
- CVL006-T1002 (NCT07157956)
- Testing
- CVL006 combined with pemetrexed and carboplatin, CVL006 in combination with SKB264, CVL006 in combination with DS-8201
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
- Trial name
- NCT07744256
- Testing
- EB-DART-NK01, Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Advanced Malignancies, NSCLC
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit…
- Conditions
- Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer
- Trial name
- NCT05059522
- Testing
- Avelumab, Lorlatanib, Talazoparib
- Where
- 71 sites in United States, Australia and 17 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Metastatic Hepatocellular Carcinoma, Solid Tumors
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic…
- Conditions
- Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
- Trial name
- SURF431 (NCT06915753)
- Testing
- TYRA-430
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 125 people
- Sponsor
- Tyra Biosciences, Inc
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 in combinations with carboplatin in advanced or metastatic refractory solid tumor…
- Trial name
- NCT06719973
- Testing
- M9466, Carboplatin, Etoposide
- Sponsor
- EMD Serono Research & Development Institute, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.